At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LUCD LUCID DIAGNOSTICS INC.
Market Closed 02-14 16:00:00 EST
1.46
+0.10
+7.35%
盘后1.51
+0.05+3.42%
19:54 EST
High1.51
Low1.33
Vol1.02M
Open1.38
D1 Closing1.36
Amplitude13.24%
Mkt Cap86.64M
Tradable Cap35.45M
Total Shares59.34M
T/O1.45M
T/O Rate4.19%
Tradable Shares24.28M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.